Search results for "renal"

showing 10 items of 1828 documents

Oral health and systemic inflammatory, cardiac and nitroxid biomarkers in hemodialysis patients.

2016

Background Periodontal diseases have systemic inflammatory effects and have been adversely associated with cardiovascular diseases, which are also the most frequent cause of death in the end-stage renal disease. The aim of this cross-sectional study was to investigate the oral health and serum biomarkers among the hemodialysis (HD) patients in Slovenia. Material and Methods 111 HD patients were periodontally examined and their sera were assayed for C reactive protein (CRP), cardiac troponin T (TnT), nitrite/nitrate (NOx) and antibody levels to A. actinomycetemcomitans and P. gingivalis. The association of oral health with systemic response was analyzed with Kruskal-Wallis test, Fisher’s exa…

0301 basic medicineMalePathologyGingival and periodontal pocketmedicine.medical_treatmentOral Health030204 cardiovascular system & hematologyGastroenterologyAggregatibacter actinomycetemcomitans0302 clinical medicineCause of deathAged 80 and overbiologyTroponin TMiddle Aged:CIENCIAS MÉDICAS [UNESCO]Antibodies Bacterial3. Good healthExact testC-Reactive ProteinUNESCO::CIENCIAS MÉDICASFemaleHemodialysismedicine.symptomAdultmedicine.medical_specialtyBleeding on probing03 medical and health sciencesTroponin TRenal DialysisInternal medicinemedicineHumansGeneral DentistryNitritesAgedNitratesOral Medicine and Pathologybusiness.industryResearchC-reactive proteinAggregatibacter actinomycetemcomitansbiology.organism_classification030104 developmental biologyCross-Sectional StudiesOtorhinolaryngologybiology.proteinSurgerybusinessBiomarkersMedicina oral, patologia oral y cirugia bucal
researchProduct

Increased Symmetric Dimethylarginine Level Is Associated with Worse Hospital Outcomes through Altered Left Ventricular Ejection Fraction in Patients …

2017

International audience; Objectives: We aimed to investigate whether SDMA-symmetric dimethylarginine-the symmetrical stereoisomer of ADMA-might be a marker of left ventricular function in AMI.Background: Asymmetric dimethylarginine (ADMA) has been implicated in the prognosis after acute myocardial infarction (AMI) and heart failure (HF).Methods: Cross sectional prospective study from 487 consecutive patients hospitalized 2, and death.Results: Patients were analysed based on SDMA tertiles. Sex, diabetes, dyslipidemia, and prior MI were similar for all tertiles. In contrast, age and hypertension increased across the tertiles (p<0.001). From the first to the last tertile, GRACE risk score was e…

0301 basic medicineMalePhysiologyPerformanceMyocardial Infarctionlcsh:MedicineBlood PressureChronic Heart-Failure030204 cardiovascular system & hematologyVascular MedicineBiochemistryVentricular Function Leftchemistry.chemical_compound0302 clinical medicineChronic Kidney DiseaseMedicine and Health SciencesCoronary Heart DiseaseDiseaseMyocardial infarctionProspective cohort studylcsh:ScienceMultidisciplinaryFramingham Risk ScoreEjection fractionAsymmetric DimethylarginineNeurochemistryMiddle AgedMetaanalysis[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemPrognosisArteryHospitals3. Good healthTreatment OutcomeImpactNephrologyHypertensionCardiologyFemaleAnatomyNeurochemicalsResearch ArticleGlomerular Filtration Ratemedicine.medical_specialtyCardiologyRenal functionNitric OxideArginine03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicinemedicineHumansRenal Insufficiency ChronicMortalityAgedHeart FailureRenal Physiologybusiness.industrylcsh:RBiology and Life SciencesRenal SystemMarkermedicine.diseaseRenal-Function030104 developmental biologychemistryHeart failurelcsh:QAsymmetric dimethylargininebusinessDyslipidemiaNeuroscience
researchProduct

Effects of nifedipine on renal and cardiovascular responses to neuropeptide y in anesthetized rats

2021

Neuropeptide Y (NPY) acts via multiple receptor subtypes termed Y1, Y2 and Y5. While Y1 receptor-mediated effects, e.g., in the vasculature, are often sensitive to inhibitors of L-type Ca2+ channels such as nifedipine, little is known about the role of such channels in Y5-mediated effects such as diuresis and natriuresis. Therefore, we explored whether nifedipine affects NPY-induced diuresis and natriuresis. After pre-treatment with nifedipine or vehicle, anesthetized rats received infusions or bolus injections of NPY. Infusion NPY (1 µg/kg/min) increased diuresis and natriuresis, and this was attenuated by intraperitoneal injection of nifedipine (3 µg/kg). Concomitant decreases in heart ra…

0301 basic medicineMaleReceptors Neuropeptidemedicine.medical_treatmentMedizinPharmaceutical ScienceOrganic chemistry030204 cardiovascular system & hematologyAnalytical ChemistryReceptors G-Protein-CoupledY<sub>1</sub> receptor0302 clinical medicineBolus (medicine)QD241-441Drug DiscoveryMedicineY1 receptorblood pressureNeuropeptide Y receptorCalcium Channel Blockershumanitiesnifedipinemedicine.anatomical_structureChemistry (miscellaneous)Molecular MedicineY5 receptormedicine.drugmedicine.medical_specialtyneuropeptide YIntraperitoneal injectionnatriuresisDiuresisArticleNatriuresis03 medical and health sciencesY<sub>5</sub> receptorNifedipineInternal medicinemental disordersAnimalsPhysical and Theoretical ChemistryRats Wistarbusiness.industryrenal blood flowRatsReceptors Neuropeptide Ydiuresis030104 developmental biologyEndocrinologyRenal blood flowVascular resistancebusiness
researchProduct

Circulation and diagnostics of Puumala virus in Norway: nephropatia epidemica incidence and rodent population dynamics.

2017

Hantaviruses pose a public health concern worldwide causing haemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS). Puumala virus (PUUV) is the most prevalent hantavirus in Central and Northern Europe, and causes a mild form of HFRS, also known as nephropathia epidemica (NE). In nature, the main host of PUUV is the bank vole (Myodes glareolus), and transmission to humans occurs through inhalation of aerosols from rodent excreta. Nephropathia epidemica is particularly prevalent in Nordic countries, however, few studies of PUUV have been performed in Norway. The aim of this study was to analyse the dynamics of PUUV in Norway and compare with bank vole population…

0301 basic medicineMaleSerumRodentanimal diseasesvirusesPopulation DynamicsSequence HomologyPolymerase Chain ReactionPuumala virusImmunology and AllergyMedicineCluster AnalysisHaemorrhagic feverChildPhylogenyAged 80 and overeducation.field_of_studybiologyArvicolinaeNorwayIncidence (epidemiology)Incidencevirus diseasesGeneral MedicineMiddle AgedChild PreschoolHemorrhagic Fever with Renal SyndromePuumala virusFemaleTopography MedicalSeasonsMicrobiology (medical)Adultmedicine.medical_specialtyAdolescent030106 microbiologyPopulationHantavirus Pulmonary SyndromeReal-Time Polymerase Chain ReactionPathology and Forensic Medicine03 medical and health sciencesYoung Adultbiology.animalAnimalsHumanseducationAgedHantavirus pulmonary syndromebusiness.industryPublic healthInfant NewbornInfantSequence Analysis DNAbiology.organism_classificationVirologyrespiratory tract diseases030104 developmental biologybusinessAPMIS : acta pathologica, microbiologica, et immunologica Scandinavica
researchProduct

An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients

2019

Background: Chronic kidney disease (CKD) is an independent risk factor for atherosclerotic disease. We hypothesized that CKD promotes a proatherogenic lipid profile modifying lipoprotein composition and particle number. Methods: Cross-sectional study in 395 non-diabetic individuals (209 CKD patients and 186 controls) without statin therapy. Conventional lipid determinations were combined with advanced lipoprotein profiling by nuclear magnetic resonance, and their discrimination ability was assessed by machine learning. Results: CKD patients showed an increase of very-low-density (VLDL) particles and a reduction of LDL particle size. Cholesterol and triglyceride content of VLDLs and intermed…

0301 basic medicineMaleVery low-density lipoproteinMagnetic Resonance SpectroscopyClinical BiochemistryMachine LearningPCSK9chemistry.chemical_compound0302 clinical medicineLp(a)Risk FactorsDrug DiscoveryProspective Studiesmedicine.diagnostic_testMiddle AgedLipids030220 oncology & carcinogenesisMolecular MedicineFemalelipids (amino acids peptides and proteins)Proprotein Convertase 9Adultmedicine.medical_specialtylipoprotein subfractionsLipoproteins03 medical and health sciencesInternal medicinemedicineHumansRisk factorRenal Insufficiency ChronicAgedPharmacologybusiness.industryCholesterolPCSK9dyslipidemiamedicine.diseaseAtherosclerosis030104 developmental biologyEndocrinologyCross-Sectional StudieschemistryCase-Control StudiesbusinessLipid profileDyslipidemiachronic kidney diseaseLipoproteinKidney disease
researchProduct

Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers

2021

Immune-related adverse events (irAEs) are a class-effect of checkpoint inhibitors (CIs). The development of a Bullous pemphigoid (BP)-like blistering disease, driven by autoantibodies against the hemidesmosomal protein BP180, is a potentially serious irAE whose incidence seems to be increasing. We therefore set out to characterize the clinical and (immuno)histopathological features and treatment responses of cases of BP which developed during or after CI therapy collated in six German tertiary referral centers between 2014 and 2018. We identified twelve cases of BP which emerged during and/or after CI therapy. The time interval between the initiation of CI therapy and the diagnosis of BP wa…

0301 basic medicineMalelcsh:Immunologic diseases. Allergymedicine.medical_specialtyPD-1 - PD-L1 axisautoantibodiesImmune checkpoint inhibitorsImmunologypemphigoid diseaseIpilimumabPembrolizumabDermatology030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineAntineoplastic Agents ImmunologicalAdrenal Cortex HormonesInternal medicineGermanyNeoplasmsPemphigoid BullousmedicineHumansImmunology and AllergyipilimumabAdverse effectImmune Checkpoint InhibitorsAgedRetrospective StudiesOriginal ResearchAged 80 and overnivolumabbusiness.industryIncidence (epidemiology)autoimmunityAutoantibodyMiddle Agedmedicine.disease030104 developmental biologyFemaleBullous pemphigoidpembrolizumabNivolumabbusinesslcsh:RC581-607checkpoint inhibitorsmedicine.drugFrontiers in Immunology
researchProduct

MUC1 deficiency mediates corticosteroid resistance in chronic obstructive pulmonary disease.

2018

Background Lung inflammation in COPD is poorly controlled by inhaled corticosteroids (ICS). Strategies to improve ICS efficacy or the search of biomarkers who may select those patients candidates to receive ICS in COPD are needed. Recent data indicate that MUC1 cytoplasmic tail (CT) membrane mucin can mediate corticosteroid efficacy in chronic rhinosinusitis. The objective of this work was to analyze the previously unexplored role of MUC1 on corticosteroid efficacy in COPD in vitro and in vivo models. Methods MUC1-CT expression was measured by real time PCR, western blot, immunohistochemistry and immunofluorescence. The inflammatory mediators IL-8, MMP9, GM-CSF and MIP3α were measured by EL…

0301 basic medicineMalemedicine.drug_classDrug ResistanceInflammationMUC1Corticosteroid resistancedigestive system03 medical and health sciencesMicePulmonary Disease Chronic Obstructive0302 clinical medicineGlucocorticoid receptorIn vivoAdrenal Cortex HormonesmedicineAnimalsHumansGene Silencingskin and connective tissue diseasesneoplasmsDexamethasoneMUC1Agedlcsh:RC705-779Mice KnockoutCOPDLungbusiness.industryResearchChronic obstructive pulmonary diseaseMucin-1Sputumlcsh:Diseases of the respiratory systemMiddle Agedmedicine.diseasedigestive system diseasesrespiratory tract diseasesMice Inbred C57BL030104 developmental biologymedicine.anatomical_structure030228 respiratory systemImmunologyCorticosteroidFemalemedicine.symptombusinessBiomarkersmedicine.drugRespiratory research
researchProduct

Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.

2019

Abstract Background Fabry disease is a rare, X-linked, lifelong progressive lysosomal storage disorder. Severely deficient α-galactosidase A activity in males is associated with the classic phenotype with early-onset, multisystem manifestations evolving to vital organ complications during adulthood. We assessed the ability of 2 low-dose agalsidase beta regimens to lower skin, plasma, and urine globotriaosylceramide (GL-3) levels, and influence clinical manifestations in male pediatric Fabry patients. Methods In this multicenter, open-label, parallel-group, phase 3b study, male patients aged 5–18 years were randomized to receive agalsidase beta at 0.5 mg/kg 2-weekly (n = 16) or 1.0 mg/kg 4-w…

0301 basic medicineMalemedicine.medical_specialtyAbdominal painAdolescentEndocrinology Diabetes and MetabolismGlobotriaosylceramideUrologyRenal function030105 genetics & heredityBiochemistrylaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyRandomized controlled triallawBiopsyGeneticsmedicineHumansEnzyme Replacement TherapyChildMolecular BiologySkinKidneymedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryTrihexosylceramidesEnzyme replacement therapymedicine.diseaseFabry diseaseIsoenzymesmedicine.anatomical_structureTreatment OutcomechemistryChild Preschoolalpha-GalactosidaseFabry Diseasemedicine.symptombusiness030217 neurology & neurosurgeryMolecular genetics and metabolism
researchProduct

Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with…

2015

The aim of this study was to assess safety and efficacy of ultrasonography (US)-guided intra-articular injections using tumor necrosis factor (TNF) blockers compared to corticosteroids in rheumatoid arthritis (RA) or psoriatic arthritis (PsA) patients, experiencing refractory monoarthritis despite the current systemic therapy. Eighty-two patients were randomized to receive three intra-articular injections monthly of either corticosteroid or TNF blockers. Primary endpoints were the safety and an improvement greater than 20% for visual analogic scales of involved joint pain in patients injected with anti-TNFα. Further clinical, US, and magnetic resonance imaging (MRI) evaluations were consid…

0301 basic medicineMalerheumatoid arthritispsoriatic arthritimagnetic resonance imaging (MRI)anti-tumor necrosis factor α agent; intra-articular injection; magnetic resonance imaging (MRI); psoriatic arthritis; rheumatoid arthritis; treat-to-target strategy; ultrasonography; Pharmacology; Immunology; Immunology and AllergyInflammatory arthritisAnti-Inflammatory Agentsanti-tumor necrosis factor α agentInjections Intra-ArticularArthritis Rheumatoid0302 clinical medicineAdrenal Cortex HormonesImmunology and Allergyintra-articular injectionpsoriatic arthritismedicine.diagnostic_testultrasonographyMiddle AgedArthralgiaRheumatoid arthritisJoint painAntirheumatic AgentsCorticosteroidTumor necrosis factor alphaFemalemedicine.symptomAdultmedicine.medical_specialtymedicine.drug_classImmunology03 medical and health sciencesPsoriatic arthritisInternal medicineMonoarthritismedicineHumansImmunologic FactorsAged030203 arthritis & rheumatologyPharmacologybusiness.industryTumor Necrosis Factor-alphaArthritis PsoriaticMagnetic resonance imagingOriginal Articlesrheumatoid arthritimedicine.diseaseSurgerytreat-to-target strategy030104 developmental biologybusiness
researchProduct

Mucoadhesive solid lipid microparticles for controlled release of a corticosteroid in the chronic obstructive pulmonary disease treatment.

2017

Therapeutic efficacy of inhaled drugs is limited by rapid clearance from the site of action due to absorption into systemic circulation or metabolic degradation by alveolar macrophages. Drug delivery systems offer new solutions to clinical problems especially in the treatment of pulmonary diseases. In particular, Solid Lipid Microparticles (SLM) in the range of 3-5 µm are suggested as systems for delivery of therapeutics to the lung as, because of their size, they are able to deposit into secondary bronchi, avoiding systemic absorption typical of alveolar regions. Here, we describe two novel different SLMs prepared with chitosan and alginate for sustained release of fluticasone propionate (…

0301 basic medicineMedicine (miscellaneous)Biocompatible Materials02 engineering and technologyPharmacologymedicine.disease_causeChitosanPulmonary Disease Chronic Obstructivechemistry.chemical_compoundDrug StabilityGlucuronic AcidAdrenal Cortex HormonesMucoadhesive Solid Lipid Nanoparticles (SLMs);Aerodynamic diameter;Chronic obstructive pulmonary disease (COPD)General Materials Sciencechronic obstructive pulmonary disease (COPD)LungChromatography High Pressure LiquidDrug CarriersHexuronic Acidsaerodynamic diameter; chronic obstructive pulmonary disease (COPD); mucoadhesive solid lipid microparticles (SLMs)021001 nanoscience & nanotechnologyLipidsControlled releasemucoadhesive solid lipid microparticles (SLMs)Microspheresmedicine.anatomical_structureDrug deliveryCorticosteroid0210 nano-technologymedicine.drugBiocompatibilityAlginatesCell SurvivalSurface Propertiesmedicine.drug_classBiomedical EngineeringBioengineeringDevelopmentFluticasone propionate03 medical and health sciencesAdministration InhalationmedicineHumansParticle Sizeaerodynamic diameterChitosanLungbusiness.industryEpithelial CellsDrug LiberationOxidative Stress030104 developmental biologychemistryDelayed-Action PreparationsImmunologyMicroscopy Electron ScanningFluticasonebusinessOxidative stress
researchProduct